Vychodoslovensky Onkologicky Ustav a.s. — Clinical Trial Site

28 Registered trials

12 Currently recruiting

Organisation

Vychodoslovensky Onkologicky Ustav a.s.

Location

Kosice, Slovakia

Identifier

ORG-100042872

Address

Rastislavova 43, Juh, 040 01, Slovakia

Departments

#2402: Oddelenie klinickej onkológie
3243:Oddelenie radiačnej onkológie
Clinical Oncology Department G
Clinical trials department
Department of Clinical Oncology
Department of Radiation Oncology
N/A
Oddelenie klinickej onkolgie
Oddelenie klinickej onkologie
Oddelenie radiacnej onkologie
Outpatient clinical oncology care in hospital
Radiation Oncology
Radiation Oncology Department

Clinical trials at this site (28)

Search interface

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo… Recruiting

2025-522093-36-00 Cancer cachexia 10 2026-05-20
Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting

2023-508057-19-00 Advanced HER2-expressing Biliary Tract Cancer 5 2025-09-23
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy. (SOLSTICE… Recruiting

2024-516180-85-00 Metastatic colorectal cancer 5 2019-04-15
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER 5 2026-01-29
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Resected or Unresectable KRAS G12C-mutant Non-Small Cel 5 2025-06-06
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617… Recruiting

2022-502956-29-00 Oligometastatic prostate cancer (OMPC) 5 2024-07-01
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Recurrent or metastatic head and neck squamous cell car 10 2024-05-22
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou… Ended

2025-522598-12-00 Untreated Metastatic Pancreatic Ductal Adenocarcinoma 10 2025-12-17
A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Ab… Ended

2024-511650-50-00 METASTATIC CASTRATION RESISTANT PROSTATE CANCER 5 2025-01-17
AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy) Ended

2024-517901-97-00 Localized or a locally advanced high-risk prostate canc 4 2023-06-13
A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended

2023-509133-39-00 Hormone receptor positive, HER2-negative advanced breas 5 2021-11-29
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended

2024-510809-28-00 Metastatic Castration-sensitive Prostate Cancer 5 2021-09-27
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended

2023-507494-18-00 Non-small cell lung cancer with ROS proto-oncogene 1, r 5 2021-09-24
The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec… Ended

2024-512038-13-00 Metastatic or unresectable locally advanced BRAF V600E/ 5 2021-09-16
A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended

2023-509405-77-00 Colorectal cancer (BRAF V600E-mutant mCRC) 5 2021-02-16
Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended

2023-505852-23-00 High risk recurrent prostate cancer previously treated 5 2020-11-12
NaDeJ (National Deescalation Study One) Ended

2024-517832-23-00 Human Papillomavirus oropharyngeal squamous cell carcin 4 2020-01-09
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended

2023-510298-33-00 Prostate Cancer 4 2016-11-29